JP6840671B2 - 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 - Google Patents
一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 Download PDFInfo
- Publication number
- JP6840671B2 JP6840671B2 JP2017539510A JP2017539510A JP6840671B2 JP 6840671 B2 JP6840671 B2 JP 6840671B2 JP 2017539510 A JP2017539510 A JP 2017539510A JP 2017539510 A JP2017539510 A JP 2017539510A JP 6840671 B2 JP6840671 B2 JP 6840671B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- fatty acids
- composition
- group
- mufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 109
- 201000001320 Atherosclerosis Diseases 0.000 title claims description 32
- 235000021281 monounsaturated fatty acids Nutrition 0.000 title description 50
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 18
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 16
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 description 60
- 235000014113 dietary fatty acids Nutrition 0.000 description 58
- 239000000194 fatty acid Substances 0.000 description 58
- 229930195729 fatty acid Natural products 0.000 description 58
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 46
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 21
- 239000011630 iodine Substances 0.000 description 21
- 229910052740 iodine Inorganic materials 0.000 description 21
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 17
- 238000002844 melting Methods 0.000 description 17
- 210000001367 artery Anatomy 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- -1 ezetimibe Chemical compound 0.000 description 14
- 230000003902 lesion Effects 0.000 description 13
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000000709 aorta Anatomy 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 125000005313 fatty acid group Chemical group 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 230000003143 atherosclerotic effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000003291 sinus of valsalva Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000010466 nut oil Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 150000002889 oleic acids Chemical class 0.000 description 3
- 235000021003 saturated fats Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 235000021068 Western diet Nutrition 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- AOHAPDDBNAPPIN-UHFFFAOYSA-N myristicinic acid Natural products COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- 244000266618 Atriplex confertifolia Species 0.000 description 1
- 235000012137 Atriplex confertifolia Nutrition 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000192497 Oscillatoria Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283249 Physeteridae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462064207P | 2014-10-15 | 2014-10-15 | |
US62/064,207 | 2014-10-15 | ||
PCT/US2015/055504 WO2016061207A1 (en) | 2014-10-15 | 2015-10-14 | Monounsaturated fatty acid compositions and use for treating atherosclerosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020130937A Division JP2020182497A (ja) | 2014-10-15 | 2020-07-31 | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017532381A JP2017532381A (ja) | 2017-11-02 |
JP2017532381A5 JP2017532381A5 (zh) | 2018-11-15 |
JP6840671B2 true JP6840671B2 (ja) | 2021-03-10 |
Family
ID=55747261
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017539510A Active JP6840671B2 (ja) | 2014-10-15 | 2015-10-14 | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 |
JP2020130937A Pending JP2020182497A (ja) | 2014-10-15 | 2020-07-31 | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020130937A Pending JP2020182497A (ja) | 2014-10-15 | 2020-07-31 | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9808437B2 (zh) |
EP (1) | EP3206677A4 (zh) |
JP (2) | JP6840671B2 (zh) |
CN (2) | CN113244206A (zh) |
BR (1) | BR112017007754B1 (zh) |
CA (1) | CA2963980A1 (zh) |
MX (1) | MX2017004839A (zh) |
WO (1) | WO2016061207A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020061956A (ja) * | 2018-10-16 | 2020-04-23 | 日本水産株式会社 | 血清中tmao低減用組成物 |
JP2022544847A (ja) * | 2019-08-21 | 2022-10-21 | バーク アンド ボイヤー、インコーポレイテッド | 一価不飽和脂肪酸組成物及び脂肪性肝疾患を治療するための使用 |
KR20240054960A (ko) * | 2021-06-11 | 2024-04-26 | 너리쉬 인그리디언츠 피티와이 리미티드 | 미생물에서의 포화 지방의 제조 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198250A (en) * | 1990-07-16 | 1993-03-30 | Lipotech Partners Limited Partnership | Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using |
US5959131A (en) * | 1995-12-07 | 1999-09-28 | Kraft Foods, Inc. | Nutritionally superior fat for food compositions |
US6391369B1 (en) * | 1996-03-27 | 2002-05-21 | Bunge Foods Corporation | Selectively hydrogenated high oleic oil compositions and process |
US6183796B1 (en) * | 1999-09-20 | 2001-02-06 | Lipotech Partners Limited Partnership | Monounsaturated fatty acid compositions and method of making |
US20090312297A1 (en) * | 2006-03-22 | 2009-12-17 | President And Fellows Of Harvard College | Methods for treating hypercholesterolemia and atherosclerosis |
US20090311367A1 (en) * | 2008-06-17 | 2009-12-17 | Perry Stephen C | Dietary Supplement |
JP6206937B2 (ja) * | 2010-10-08 | 2017-10-04 | 和久 前田 | マッサージ施療による経皮投与用の血流依存性血管拡張反応改善剤及び血糖値低下剤、並びに生体用貼付シート |
MX2013010076A (es) | 2011-03-03 | 2014-04-07 | Tersus Pharmaceuticals Llc | Composiciones y metodos que comprenden c16:1n7 palmitoleato. |
ITMI20111284A1 (it) * | 2011-07-11 | 2013-01-12 | Giovanni Nusca | Composizione farmaceutica. |
WO2014054048A1 (en) * | 2012-10-01 | 2014-04-10 | Dow Global Technologies Llc | Triglyceride based, low viscosity, high flash point dielectric fluids |
-
2015
- 2015-10-14 EP EP15849843.6A patent/EP3206677A4/en active Pending
- 2015-10-14 CN CN202110447856.3A patent/CN113244206A/zh active Pending
- 2015-10-14 JP JP2017539510A patent/JP6840671B2/ja active Active
- 2015-10-14 CA CA2963980A patent/CA2963980A1/en not_active Abandoned
- 2015-10-14 BR BR112017007754-0A patent/BR112017007754B1/pt active IP Right Grant
- 2015-10-14 US US15/113,739 patent/US9808437B2/en active Active - Reinstated
- 2015-10-14 CN CN201580055855.7A patent/CN106794165A/zh active Pending
- 2015-10-14 MX MX2017004839A patent/MX2017004839A/es unknown
- 2015-10-14 WO PCT/US2015/055504 patent/WO2016061207A1/en active Application Filing
-
2020
- 2020-07-31 JP JP2020130937A patent/JP2020182497A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016061207A1 (en) | 2016-04-21 |
JP2017532381A (ja) | 2017-11-02 |
CN106794165A (zh) | 2017-05-31 |
BR112017007754A2 (pt) | 2018-08-28 |
EP3206677A1 (en) | 2017-08-23 |
US9808437B2 (en) | 2017-11-07 |
MX2017004839A (es) | 2017-10-12 |
CN113244206A (zh) | 2021-08-13 |
CA2963980A1 (en) | 2016-04-21 |
US20170216237A1 (en) | 2017-08-03 |
EP3206677A4 (en) | 2018-04-25 |
JP2020182497A (ja) | 2020-11-12 |
BR112017007754B1 (pt) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5827784B2 (ja) | ビタミンk2を含む医薬及び栄養補助製品 | |
KR0126286B1 (ko) | 지방산 조성물 | |
JP2020182497A (ja) | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 | |
Billman et al. | Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs | |
US20080113046A1 (en) | Use of Omega-3 Fatty Acid(s) for Treating Hypercholesterolemia Caused by Anti-Retroviral Treatment of Hiv-Infected Patients | |
SK10802001A3 (sk) | Esenciálne mastné kyseliny na prevenciu kardiovaskulárnych príhod | |
JP2021508343A (ja) | リゾホスファチジルコリン組成物 | |
KR20120065276A (ko) | 지질 조성을 조정하기 위한 조성물 및 방법 | |
JP2007262050A (ja) | アディポネクチン産生増強剤 | |
JP2015180640A (ja) | バイオオイル組成物、上記オイル組成物を含む製剤と、循環器疾患の予防又は治療のためのその使用 | |
BE876563A (fr) | Acide gras et ses derives pour le traitement ou la prophylaxie des etats thrombo-emboliques | |
US20210251932A1 (en) | Method Of Treatment Of Obesity | |
JP6067558B2 (ja) | 恐怖記憶の軽減方法 | |
JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
JPH01156922A (ja) | 悩疾患治療用薬剤の製造方法と治療用化合物 | |
TW201827047A (zh) | 用於預防及/或治療惡病質的ω-3脂肪酸組合物 | |
JP2000281572A (ja) | 殺癌細胞剤及びこれを配合してなる組成物 | |
JP2000239168A (ja) | 脳卒中予防剤およびこれを配合してなる組成物 | |
JP4139677B2 (ja) | 記憶障害改善作用を有する組成物 | |
RU2520695C1 (ru) | Комплекс биологически активных веществ для лечения и профилактики заболеваний сердечно-сосудистой системы | |
JPWO2015005393A1 (ja) | 大動脈瘤の予防または治療剤および容器詰飲食品 | |
Kensara et al. | Aqueous extract of Thymus Vulgaris-induced prevention of kidney damage in hypertensive adult male albino rat: Biochemical and ultrastructural study | |
JPH02235811A (ja) | 嚢胞腎の治療剤 | |
JPS6011421A (ja) | 血中脂質降下剤 | |
JP2000086425A (ja) | 美白剤およびこれを配合してなる美白用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181002 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181002 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190920 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200731 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200731 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20200731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200803 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200901 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201026 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6840671 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |